SCHEMBL9611048

SCHEMBL9611048

Cc1ccc(CNC(=O)c2nnc(-c3cccc(NS(=O)(=O)C(F)(F)F)c3)o2)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 3/20 0.49
POLB P06746 1/20 0.49
PPARA Q07869 6/20 0.44
NPC1 O15118 2/20 0.44
RAB9A P51151 2/20 0.44
RXFP1 Q9HBX9 1/20 0.44
MAPK1 P28482 2/20 0.44
NPSR1 Q6W5P4 3/20 0.44
FBP1 P09467 3/20 0.44
TSHR P16473 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
HSD17B10 Q99714 2/20 0.44
USP2 O75604 1/20 0.44
LMNA P02545 1/20 0.44
PPARG P37231 2/20 0.43
PPARD Q03181 1/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
MAPK14 Q16539 1/20 0.42
MAPT P10636 3/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL691309 0.91 EPHX2 (0.48) TP53POLBPPARASMN1; SMN2USP2
SCHEMBL691959 0.88 MAPK14 (0.44) TP53PPARANPC1RAB9AMAPK1
SCHEMBL9611047 0.81 SMN1; SMN2 (0.48) NPC1RAB9ARXFP1MAPK1NPSR1
SCHEMBL692852 0.80 CA1 (0.52) TP53POLBNPC1RAB9ARXFP1
SCHEMBL691544 0.79 PPARA (0.54) PPARAPPARGPPARDMAPK14
SCHEMBL692005 0.77 PPARA (0.49) PPARASMN1; SMN2HSD17B10LMNAPPARG
SCHEMBL691261 0.74 PRMT6 (0.41) POLBMAPK1NPSR1FBP1TSHR
SCHEMBL9611041 0.72 MAPK1 (0.57) TP53POLBMAPK1LMNAMEN1
SCHEMBL692662 0.70 USP2 (0.44) TSHRUSP2LMNAMEN1KMT2A
SCHEMBL28603386 0.69 NPC1 (0.56) TP53POLBNPC1RAB9AMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120136003-A1 COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING 1,3,4-OXADIAZOLE DERIVATIVES INSTITUTE FOR ONEWORLD HEALTH 2012-05-31 US disclosed
US-20110288103-A1 COMPOUNDS, COMPOSITIONS, AND METHODS COMPRISING 1,3,4-OXADIAZOLE DERIVATIVES INSTITUTE FOR ONEWORLD HEALTH 2011-11-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120136003-A1 COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING 1,3,4-OXADIAZOLE DERIVATIVES CFTR, PKD1, PKD2 TP53 1900/4885POLB 3401/4885PPARA 1464/4885
US-20110288103-A1 COMPOUNDS, COMPOSITIONS, AND METHODS COMPRISING 1,3,4-OXADIAZOLE DERIVATIVES ORAI1, ATP2A3, ANO1 TP53 3985/4885POLB 4092/4885PPARA 2817/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.